Six Open Clinical Trials That Are Expanding Our Understanding of Immunotherapies

Colorectal cancer, melanoma, multiple myeloma, and acute lymphoblastic leukemia are among the types of diseases that are being targeted.


Using the immune system to help fight cancer is one of newest and most promising directions in cancer research. While many of the findings so far remain preliminary, a number of new studies are being developed or are already underway. Not surprisingly, federal oncologists and hematologists are leading the way with ground-breaking research. Importantly, a number of trials are recruiting patients at VA facilities. Here are a few of the studies already underway:

Study: Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

Sponsor: National Cancer Institute

This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer over time. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.

Federal Study Locations (7 total): Kansas City VAMC


Recommended Reading

Glimmer of promise for nivolumab in neoadjuvant NSCLC therapy
Federal Practitioner
Pembrolizumab boosts response but not survival in small study of advanced NSCLC
Federal Practitioner
Change in end-of-life cancer care imperative
Federal Practitioner
Pembrolizumab ‘new standard of care’ in advanced PD-L1-rich NSCLC
Federal Practitioner
Nivolumab + ipilimumab induced fulminant, fatal myocarditis
Federal Practitioner